MD  >> Vol. 6 No. 4 (December 2016)

    不同肿瘤染色体的扩增分析
    The Analysis of Chromosome Amplification in Different Tumors

  • 全文下载: PDF(337KB) HTML   XML   PP.89-93   DOI: 10.12677/MD.2016.64016  
  • 下载量: 497  浏览量: 1,856  

作者:  

刘博,王智:第四军医大学,一旅二营七连,陕西 西安;
刘一雄,范林妮:第四军医大学基础部,陕西 西安

关键词:
染色体肿瘤扩增Chromosome Tumors Amplification

摘要:

随着越来越多的科研学者将肿瘤关注的重点投入到基因方面,染色体扩增与恶性肿瘤的关系不断被揭示和验证。本文通过探讨不同恶性肿瘤中染色体变异情况,揭示了常见染色体突变的规律,同时简洁地为临床上新的检测方法和治疗靶点提供了依据。有助于新技术和新药物的应用开展。

As more and more scientific research scholars focus on the tumor gene, the relationship between chromosome amplification and malignant tumors has been revealed and validated. By discussing the chromosome variation in different malignant tumors, this paper reveals the rule of common chromosome mutations, concisely provides the new detection methods and clinical therapeutic targets and helps the application of new technologies and drugs.

文章引用:
刘博, 王智, 刘一雄, 范林妮. 不同肿瘤染色体的扩增分析[J]. 医学诊断, 2016, 6(4): 89-93. http://dx.doi.org/10.12677/MD.2016.64016

参考文献

[1] 王彦. 多倍体细胞与肿瘤关系的研究进展[J]. 国际妇产科学杂志, 2010, 37(6): 420-422.
[2] Tse, C.H., Hwang, H.C., Goldstein, L.C., Kandalaft, P.L., Wiley, J.C., Kussick, S.J. and Gown, A.M. (2011) Determining True HER2 Gene Status in Breast Cancers with Polysomy by Using Alternative Chromosome 17 Reference Genes: Implications for Anti-HER2 Targeted Therapy. Journal of Clinical Oncology, 29, 4168-4174.
https://doi.org/10.1200/JCO.2011.36.0107
[3] Tibau, A., López-Vilaró, L., Pérez-Olabarria, M., Vázquez, T., Pons, C., Gich, I., et al. (2014) Chromosome 17 Centromere Duplication and Responsiveness to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer. Neoplasia, 16, 861-867.
https://doi.org/10.1016/j.neo.2014.08.012
[4] Afify, A. and Mark, H.F.L. (1997) Fluorescence in Situ Hybridization Assessment of Chromosome 8 Copy Number in Stage I and Stage II Infiltrating Ductal Carcinoma of the Breast. Cancer Genetics and Cytogenetics, 97, 101-105.
https://doi.org/10.1016/S0165-4608(96)00361-5
[5] Watters, A.D., Going, J.J., Cooke, T.G. and Bartlett, J.M.S. (2003) Chromosome 17 Aneusomy Is Associated with Poor Prognostic Factors in Invasive Breast Carcinoma. Breast Cancer Re-search and Treatment, 77, 109-114.
https://doi.org/10.1016/j.neo.2014.08.012
[6] Krishnamurti, U., Hammers, J.L., Atem, F.D., Storto, P.D. and Silverman, J.F. (2009) Poor Prognostic Significance of Unamplified Chromosome 17 Polysomy in Invasive Breast Carcinoma. Modern Pathology, 22, 1044-1048.
https://doi.org/10.1038/modpathol.2009.61
[7] Pritchard, K.I., Munro, A., O’Malley, F.P., Tu, D.S., Li, X., Levine, M.N., et al. (2012) Chromosome 17 Centromere (CEP17) Duplication as a Predictor of Anthracycline Response: Evidence from the NCIC Clinical Trials Group (NCLC CTG) MA.5 Trial. Breast Cancer Research and Treatment, 131, 541-551.
https://doi.org/10.1007/s10549-011-1840-4
[8] Bartlett, J.M., Munro, A.F., Dunn, J.A., McConkey, C., Jordan, S., Twelves, C.J., et al. (2010) Predictive Markers of Anthracycline Benefit: A Prospectively Planned Analysis of the UK National Epirubicin Adjuvant Trial (NEAT/ BR9601). The Lancet Oncology, 11, 266-274.
https://doi.org/10.1016/S1470-2045(10)70006-1
[9] 李璐. 肺癌染色体非整倍体的间期核荧光原位杂交研究[D]: [博士学位论文]. 北京: 中国协和医科大学, 2007.
[10] Kubokura H., et al. (2001) Relations of the c-myc Gene and Chromosome 8 in Non-Small Cell Lung Cancer: Analysis by Fluorescence in Situ Hybridization. Annals of Thoracic and Cardiovascular Surgery, 7, 197-203.
[11] Yakut, T., Egeli, U. and Gebitekin, C. (2003) Investigation of c-Myc and p53 Gene Alterations in the Tumor and Surgical Borderline Tissues of NSCLC and Effects on Clinicopathologic Behavior: By the FISH Technique. Lung, 181, 245-258.
https://doi.org/10.1007/s00408-003-1026-x
[12] Chen, Y.Y. and Xu, G. (2014) Effect of Circulating Tumor Cells Combined with Negative Enrichment and CD45-FISH Identification in Diagnosis, Therapy Monitoring and Prognosis of Primary Lung Cancer. Medical Oncology, 31, 240.
https://doi.org/10.1007/s12032-014-0240-0
[13] Wilkens, L., et al. (2001) Diagnostic Impact of Fluorescence in Situ Hybridization in the Differentiation of Hepatocellular Adenoma and Well-Differentiated Hepatocellular Carcinoma. Journal of Molecular Diagnostics, 3, 68-73.
https://doi.org/10.1016/S1525-1578(10)60654-X
[14] Nasarek, A., Werner, M., Nolte, M., Georgii, A. and Klempnauer, J. (1995) Trisomy 1 and 8 Occur Frequently in Hepatocellular Carcinoma but Not in Liver Cell Adenoma and Focal Nodu-larhyperplasis. A Fluorescence in Situ Hybridization Study. Virchows Archiv, 427, 373-378.
https://doi.org/10.1007/BF00199385
[15] Wilkens, L., et al. (2004) Induction of Aneuploidy by Increasing Chromo-somal Instability during Dedifferentiation of Hepatocellular Carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 101, 1309-1314.
https://doi.org/10.1073/pnas.0305817101
[16] Sayagués, J.M., et al. (2010) Intratumoural Cytogenetic Heterogeneity of Sporadic Colorectal Carcinomas Suggests Several Pathways to Liver Metastasis. Journal of Pathology, 221, 308-319.
https://doi.org/10.1002/path.2712
[17] Galimi, F., et al. (2011) Genetic and Expression Analysis of MET, MACC1, and HGFin Metastatic Colorectal Cancer: Response to Met Inhibitionin Patient Xenografts and Pathologic Correlations. Clinical Cancer Research, 17, 3146- 3156.
https://doi.org/10.1158/1078-0432.CCR-10-3377
[18] Hu, J., Khanna, V., Jones, M.M.W. and Surti, U. (2002) Genomic Imbalances in Ovarian Borderline Serous and Mucinous Tumors. Cancer Genetics and Cytogenetics, 139, 18-23.
https://doi.org/10.1016/S0165-4608(02)00603-9
[19] Darcy, K.M., et al. (2009) Prognostic Relevance of c-MYC Gene Amplification and Polysomy for Chromosome 8 in Suboptimally-Resected, Advanced Stage Epithelial Ovarian Cancers: A Gynecologic Oncology Group Study. Gynecologic Oncology, 114, 472-479.
https://doi.org/10.1016/j.ygyno.2009.05.012
[20] Ning, N., et al. (2014) Improvement of Specific Detection of Circu-lating Tumor Cells Using Combined CD45 Staining and Fluorescence in Situ Hybridization. Clinica Chimica Acta, 433, 69-75.
https://doi.org/10.1016/j.cca.2014.02.019
[21] Zojer, N., et al. (1998) Chromosomal Imbalances in Primary and Metastatic Pancreatic Carcinoma as Detected by Interphase Cytogenetics: Basic Findings and Clinical Aspects. British Journal of Cancer, 77, 1337-1342.
https://doi.org/10.1038/bjc.1998.223
[22] Schleger, C., Verbeke, C., Hildenbrand, R., Zentgraf, H. and Bley, U. (2002) C-MYC Activation in Primary and Metastatic Ductal Adenocarcinoma of the Pancreas: Incidence, Mechanisms, and Clinical Significance. Modern Pathology, 15, 462-469.
https://doi.org/10.1038/modpathol.3880547
[23] Zhang, Y., et al. (2015) Patterns of Circulating Tumor Cells Identified by CEP8, CK and CD45 in Pancreatic Cancer. International Journal of Cancer, 136, 1228-1233.
https://doi.org/10.1002/ijc.29070
[24] Ciesielski, M., et al. (2014) The HER2 Gene and HER2 Protein Status and Chromosome 17 Polysomy in Gastric Cancer Cells in Own Material. Applied Immunohistochemistry & Molecular Morphology, 23, 113-117.
https://doi.org/10.1097/PAI.0000000000000070
[25] Li, Y., et al. (2014) Clinical Significance of Phenotyping and Karyotyping of Circulating Tumor Cells in Patients with Advanced Gastric Cancer. Oncotarget, 5, 6594-6602.
https://doi.org/10.18632/oncotarget.2175